Association of IL-12, IL-18 variants and serum IL-18 with bladder cancer susceptibility in North Indian population

Gene

Volumn 519, Issue 1, 2013, Pages 128-134

  Jaiswal, Praveen Kumar ^a   Singh, Vibha ^a   Srivastava, Priyanka ^a   Mittal, Rama Devi ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

BCG; Bladder cancer; ELISA; IL 12; IL 18; Polymorphism

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 18;

ADULT; ALLELE; AMPLIFICATION REFRACTORY MUTATION SPECIFIC POLYMERASE CHAIN REACTION; ARTICLE; BLADDER CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; RECURRENCE RISK; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AGED; ALLELES; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; INDIA; INTERLEUKIN-12; INTERLEUKIN-18; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84875382601     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.01.025     Document Type: Article

References (33)

1. Asefi V., Mojtahedi Z., Khademi B., Naeimi S., Ghaderi A. A head and neck squamous cell carcinoma is not associated with interleukin 18 promoter gene polymorphisms: a case-control study. J. Laryngol. Otol. 2009, 123:444-448.
2. Baxevanis C.N., Gritzapis A., Papamichail M. In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18. J. Immunol. 2003, 171:2953-2959.
3. Ben Chaaben A., et al. Association of IL-12 p40+1188 A/C polymorphism with nasopharyngeal cancer risk and tumor extension. Tissue Antigens 2011, 78:148-151.
4. Colombel, M., Soloway, M., Akaza, H., 2008. Epidemiology, staging, grading and risk stratification of bladder cancer. Eur. Urol. (Suppl.7), 618-626.
5. Farhat K., Hassen E., Bouzgarrou N., Gabbouj S., Bouaouina N., Chouchane L. Functional IL-18 promoter gene polymorphisms in Tunisian nasopharyngeal carcinoma patients. Cytokine 2008, 43:132-137.
6. Farjadfar A., Mojtahedi Z., Ghayumi M.A. Interleukin-18 promoter polymorphism is associated with lung cancer: a case-control study. Acta Oncol. 2009, 48:971-976.
7. Giedraitis V., He B., Huang W.X., Hillert J. Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J. Neuroimmunol. 2001, 112:146-152.
8. Haghshenas M.R., Hosseini S.V., Mahmoudi M., Saberi-Firozi M., Farjadian S., Ghaderi A. IL-18 serum level and IL-18 promoter gene polymorphism in Iranian patients with gastrointestinal cancers. J. Gastroenterol. Hepatol. 2009, 24:1119-1122.
9. Huang D., Cancilla M.R., Morahan G. Complete primary structure, chromosomal localisation, and definition of polymorphism of the gene encoding the human interleukin-12 p40 subunit. Genes Immun. 2000, 1:515-520.
10. Khalili-Azad T., et al. Association of interleukin-18 gene promoter polymorphisms with breast cancer. Neoplasma 2009, 56:22-25.
11. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern. Med. Rev. 2003, 8:223-246.
12. Lebel-Binay S., et al. Interleukin-18: biological properties and clinical implications. Eur. Cytokine Netw. 2000, 11:15-26.
13. Lin W.W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 2007, 117:1175-1183.
14. Liu Y., Lin N., Huang L., Xu Q., Pang G. Genetic polymorphisms of the interleukin-18 gene and risk of prostate cancer. DNA Cell Biol. 2007, 26:613-618.
15. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988, 16:1215.
16. Naeimi S., Ghiam A.F., Mojtahedi Z., Dehaghani A.S., Amani D., Ghaderi A. Interleukin-18 gene promoter polymorphisms and recurrent spontaneous abortion. Eur. J. Obstet. Gynecol. Reprod. Biol. 2006, 128:5-9.
17. Nakanishi K., Yoshimoto T., Tsutsui H., Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 2001, 12:53-72.
18. Nikiteas N., Yannopoulos A., Chatzitheofylaktou A., Tsigris C. Heterozygosity for interleukin-18-607A/C polymorphism is associated with risk for colorectal cancer. Anticancer. Res. 2007, 27:3849-3853.
19. Nong L.G., Luo B., Zhang L., Nong H.B. Interleukin-18 gene promoter polymorphism and the risk of nasopharyngeal carcinoma in a Chinese population. DNA Cell Biol. 2009, 28:507-513.
20. Okamoto M., et al. Correlation of decreased survival and IL-18 in bone metastasis. Intern. Med. 2009, 48:763-773.
21. Pratesi C., et al. Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol. Immunother. 2006, 55:23-30.
22. Qi T., Wang Q., Zheng L., Yang H.L., Bao J. Correlation of serum IL-18 level and IL-18 gene promoter polymer phisms to the risk of cervical cancer. Nan Fang Yi Ke Da Xue Xue Bao 2008, 28:754-757.
23. Sáenz-López P., et al. Impact of interleukin-18 polymorphisms-607 and -137 on clinical characteristics of renal cell carcinoma patients. Hum. Immunol. 2010, 71:309-313.
24. Samsami Dehaghani A., et al. Interleukin-18 gene promoter and serum level in women with ovarian cancer. Mol. Biol. Rep. 2009, 36:2393-2397.
25. Seegers D., Zwiers A., Strober W., Pena A.S., Bouma G. A TaqI polymorphism in the 3'UTR of the IL-12 p40 gene correlates with increased IL-12 secretion. Genes Immun. 2002, 3:419-423.
26. Sobti R.C., Shekari M., Tamandani D.M., Malekzadeh K., Suri V. Association of interleukin-18 gene promoter polymorphismon the risk of cervix carcinogenesis in north Indian population. Oncol. Res. 2008, 17:159-166.
27. Sobti R.C., et al. Insights into the role of IL-12B and IFN-γ cytokine gene polymorphisms in HIV-1/AIDS infection. Folia Biol. 2010, 56:110-115.
28. Thalmann G.N., Sermier A., Rentsch C., Mohrle K., Cecchini M.G., Studer U.E. Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J. Urol. 2000, 164:2129-2133.
29. Trinchieri G., Gerosa F. Immunoregulation by interleukin-12. J. Leukoc. Biol. 1996, 59:505-511.
30. Tsai J.P., Chen H.W., Cheng M.L. Analysis of host versus tumor interaction in cancer patients: opposing role of transforming growth factor-h1and interleukin-6 in the development of in situ tumor immunity. Immunobiology 2005, 210:661-671.
31. United States Cancer Statistics 1999-2007 Incidence and Mortality Web based Report 2010, Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute, Atlanta (GA), (Available at: http://www.cdc.gov/uscs).
32. Wei Y., Lan Y., Liu Y.G., Hui Tang Interleukin-18 gene promoter polymorphisms and the risk of esophageal squamous cell carcinoma. Acta Oncol. 2007, 46:1090-1096.
33. Zhao B., Meng L.Q., Huang H.N., Pan Y., Xu Q.Q. A novel functional polymorphism, 16974 A/C, in the interleukin-12-3' untranslated region is associated with risk of glioma. DNA Cell Biol. 2009, 28:335-341.